EXONICS THERAPEUTICS
Exonics’ laboratory has demonstrated the ability to use adeno-associated virus (AAV) to deliver a payload based on CRISPR/Cas9 technology that can identify and correct exon mutations that prevent the production of dystrophin, a protein that helps stabilize and protect muscle fibers.
EXONICS THERAPEUTICS
Industry:
Biopharma Biotechnology Medical Device Therapeutics
Founded:
2016-11-30
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.exonicstx.com
Total Employee:
11+
Status:
Closed
Contact:
(857)288-1518
Email Addresses:
[email protected]
Total Funding:
45 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Mimecast Proofpoint Media Temple MediaTemple DNS Workable
Similar Organizations
Cero Therapeutics
CERo Therapeutics, Inc. is a new cellular immunotherapy company.
CuraSen Therapeutics
CuraSen Therapeutics is a biopharmaceutical company.
Cygnal Therapeutics
Cygnal Therapeutics is a biotechnology company
Emendo Biotherapeutics
Emendo Biotherapeutics is a biotechnology company
Enterin
Philadelphia-based biotechnology company .
ExCellThera
ExCellThera is an advanced clinical stage biotechnology company.
Feldan Therapeutics
Feldan Therapeutics has developed a patented peptide-based technology platform.
January Therapeutics
January Therapeutics is a San Diego-based biotechnology company.
MOMA Therapeutics
MOMA Therapeutics operates as a biotechnology company.
OxSonics Therapeutics
OxSonics® Therapeutics’ proprietary drug delivery platform technology, SonoTran®
Xios Therapeutics
Xios Therapeutics is a biotechnology company .
Current Employees Featured
Founder
Investors List
The Column Group
The Column Group investment in Series A - Exonics Therapeutics
CureDuchenne Ventures
CureDuchenne Ventures investment in Seed Round - Exonics Therapeutics
More informations about "Exonics Therapeutics"
Exonics Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Phone Number (857)288-1518 Exonics’ laboratory has demonstrated the ability to use adeno-associated virus (AAV) …See details»
Exonics Therapeutics - VentureRadar
Casebia has its own scientific leadership and management team, this enables the Company to run as an independent and sustainable organization separate from the investing partners. …See details»
Exonics - 2025 Company Profile, Funding & Competitors - Tracxn
Mar 8, 2025 Exonics is an early-stage biotech start-up developing CRISPR/Cas-9 gene editing therapies for Duchenne's Muscular Dystrophy. The company has been formed as a spin-out …See details»
Exonics Therapeutics - PitchBook
Exonics Therapeutics General Information Description. Developer of gene repair therapies designed for devastating genetic neuromuscular diseases. The company's uses CRISPR/Cas9 technology which is a potential one-time …See details»
Exonics Therapeutics Company Overview, Contact Details
Vertex Pharmaceuticals acquired Exonicstx for $245M on Jun 1st '19. Vertex announced plans to acquire Exonics Therapeutics for approximately $1 billion, as well as spend an additional up-to …See details»
Exonics Therapeutics Launches with Funding from CureDuchenne …
BOSTON – February 27, 2017 – Exonics Therapeutics, Inc., a newly formed biotechnology company focused on developing gene editing technologies like CRISPR/Cas9 to permanently …See details»
CureDuchenne Ventures Invests in New Gene Editing Company …
Feb 27, 2017 NEWPORT BEACH, Calif., February 27, 2017 – CureDuchenne Ventures, a subsidiary of the nonprofit CureDuchenne that funds research to find a cure for Duchenne …See details»
Exonics Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Mar 7, 2025 www.exonicstx.com. Startups | Subsidiary Company | 2016 | Massachusetts, United States | 10-50 | www.exonicstx.com. Last update 07 Mar 2025. Overview. Pipeline. Deal. …See details»
Exonics Therapeutics - Ownership and Business Overview - Mergr
Jun 6, 2019 United States, www.exonicstx.com. Profile Investors (1) Analytics Exonics Therapeutics, Inc. is developing gene editing therapies to treat patients with DMD and other …See details»
Exonics Therapeutics Raises $40 Million in Series A Financing
Nov 8, 2017 For more information, please visit www.exonicstx.com. About The Column Group The Column Group (TCG) is a leading venture capital firm based in San Francisco that seeks …See details»
Exonics Therapeutics (USA) Funding: $45M - Medical Startups
Mar 11, 2025 Exonics Therapeutics is developing transformative SingleCut CRISPR gene repair therapies for devastating genetic neuromuscular...See details»
Exonics’s Competitors, Revenue, Number of Employees, Funding
Exonics’s Profile, Revenue and Employees. Exonics is a biotechnology company that focuses on provding gene repair therapies for genetic neuromuscular diseases. Exonics’s primary …See details»
Exonics Therapeutics - Craft
Exonics Therapeutics develops gene editing technologies to permanently correct the majority of duchenne muscular dystrophy mutations. The Company’s laboratory has demonstrated the …See details»
Exonics Therapeutics Launches with Funding from - GlobeNewswire
Feb 27, 2017 Corporate Contact Jak Knowles, MD Exonics Therapeutics [email protected] Media Contact Tony Plohoros 6 Degrees [email protected] (908) 591-2839 Contact …See details»
Exonics Therapeutics Company Information - Funding, Investors, …
Get information on funding, investors, industries, and more for Exonics Therapeutics. See Exonics Therapeutics company profile and funding data.See details»
Exonics Therapeutics CEO and key executive team | Craft.co
Exonics Therapeutics's Chairman is David Goeddel. Other executives include Jj Kang, Board Member; Eric Olson, Founder and Board Observer and 2 others. See the full leadership team …See details»
Vertex agrees to acquire Exonics Therapeutics for $245m
Vertex to acquire Exonics Therapeutics for $245m. Vertex Pharmaceuticals has signed a definitive agreement to acquire all outstanding shares of gene editing therapies developer …See details»
Vertex Expands into New Disease Areas and… | CRISPR Therapeutics
Exonics’ technology is licensed from UT Southwestern Medical Center and is based on the research of Eric Olson, Ph.D., Exonics’ founder and chief science advisor. Exonics is located …See details»
UT Southwestern-Linked Startup Exonics Therapeutics Exits in Deal ...
Jun 17, 2019 Exonics Therapeutics, a Massachusetts-based biotech company that uses technology licensed from UT Southwestern Medical Center in Dallas, is being acquired by …See details»
Exonics Therapeutics Raises $40 Million in Series A - GlobeNewswire
Nov 8, 2017 “As a leading research organization focused on Duchenne muscular dystrophy, CureDuchenne, through CureDuchenne Ventures, is proud to support the work of Dr. Eric …See details»